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Background: The world health organization (WHO) has identified the 
need for a better understanding of which patients with hepatitis C 
virus (HCV) can be cured with ultrashort course HCV therapy. 
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Methods: A total of 202 individuals with chronic HCV were 
randomised to fixed-duration shortened therapy (8 weeks) vs variable-
duration ultrashort strategies (VUS1/2). Participants not cured 
following first-line treatment were retreated with 12 weeks’ 
sofosbuvir/ledipasvir/ribavirin. The primary outcome was sustained 
virological response 12 weeks (SVR12) after first-line treatment and 
retreatment. Participants were factorially randomised to receive 
ribavirin with first-line treatment. 
Results: All evaluable participants achieved SVR12 overall (197/197, 
100% [95% CI 98-100]) demonstrating non-inferiority between fixed-
duration and variable-duration strategies (difference 0% [95% CI -
3.8%, +3.7%], 4% pre-specified non-inferiority margin). First-line SVR12 
was 91% [86%-97%] (92/101) for fixed-duration vs 48% [39%-57%] 
(47/98) for variable-duration, but was significantly higher for VUS2 
(72% [56%-87%] (23/32)) than VUS1 (36% [25%-48%] (24/66)). Overall, 
first-line SVR12 was 72% [65%-78%] (70/101) without ribavirin and 68% 
[61%-76%] (69/98) with ribavirin (p=0.48). At treatment failure, the 
emergence of viral resistance was lower with ribavirin (12% [2%-30%] 
(3/26)) than without (38% [21%-58%] (11/29), p=0.01). 
Conclusions: Unsuccessful first-line short-course therapy did not 
compromise retreatment with sofosbuvir/ledipasvir/ribavirin (100% 
SVR12). SVR12 rates were significantly increased when ultrashort 
treatment varied between 4-7 weeks rather than 4-6 weeks. Ribavirin 
significantly reduced resistance emergence in those failing first-line 
therapy. 
ISRCTN Registration: 37915093 (11/04/2016).
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Introduction
The recent and rapid development of treatment for hepatitis 
C virus (HCV) has enabled an ambitious strategy for the 
elimination of viral hepatitis as a global public health threat 
by 2030, with the target of treating 80% of those chronically 
infected with HCV1. Although licensed durations of 8–12 
weeks’ therapy with directly acting antivirals (DAAs) are sig-
nificantly shorter, more tolerable and more effective than 
previous interferon-based therapies2, there are patients who still 
find it challenging to complete a full treatment course. Such 
patients will become an increasingly important part of clini-
cal practice as treatment coverage expands to reach marginal-
ised groups, and world health organization (WHO) treatment 
guidelines highlight the need to understand the factors that 
could be used to select patients for successful short course 
treatment3.
Shorter treatment courses of licensed therapies are likely 
to improve adherence, including in those with active illicit 
drug use4,5. In acute or recent HCV infection, shortened courses 
of licensed therapy may have sufficiently high efficacy to be 
recommended routinely6. However, in chronic infection there 
is limited data to select patients able to achieve high cure 
rates with short duration therapy. Unselected short duration 
treatment has been able to achieve cure rates of 20–40% with 4 
weeks and 57–95% with 6 weeks treatment in small Phase II 
studies7–9, but few of these combinations or durations were sub-
sequently licensed for use. For licensed therapies, baseline 
viral load (<6,000,000 IU/mL)10 and subgenotype11 have been 
recommended to shorten therapy from 12 to 8 weeks, but 
there are no validated criteria to recommend less than 8 weeks 
therapy in chronic infection.
For a clinician deciding whether to start treatment in a patient 
considered at high risk of not completing therapy, there is 
a potential concern that emerging resistance with virologi-
cal failure may compromise future treatment options. However, 
it is also possible that with shorter courses of treatment, less 
resistance may emerge. In vitro evidence suggests the addition of 
ribavirin, a generically available guanosine analogue, may 
improve rates of virological cure with shorter treatment 
courses12 and could reduce the emergence of resistance in those 
failing treatment when added to short-course therapy13. However, 
these hypotheses have not been tested in a randomised trial.
We performed a strategic post-licensing randomised control-
led trial in HCV-infected participants with mild liver disease to 
evaluate strategies for short-course treatment, the impact of 
treatment failure on retreatment and the role of adjunctive 
ribavirin in short-course therapy.
Methods
Design
We conducted a multi-centre, randomised, open-label, facto-
rial, parallel group non-inferiority trial of adults with mild 
chronic HCV in 14 UK centres (Figure 1). The trial was approved 
by the Cambridgeshire South Research Ethics Committee 
(15/EE/0435). The trial was registered at ISRCTN (37915093, 
11th April 2016), and EudraCT (2015-005004-28, 31st Decem-
ber 2015). This study is reported in line with the Consolidated 
Standards of Reporting Trials (CONSORT)14.
Participants
Eligible participants were adults (≥18 years) infected with 
HCV genotype 1a/1b/4 for ≥6 months, with consistently 
detectable viremia 6 months before randomisation, no evidence 
of significant liver fibrosis (Fibroscan score ≤7.1kPa equiva-
lent to F0-F115), body mass index (BMI) ≥18kg/m2, HCV viral 
load (VL) detectable but <10 million IU/ml at screening, no 
previous DAA exposure for current infection (previous 
pegylated-interferon/ribavirin allowed) and with laboratory 
results meeting minimum thresholds (platelets ≥60×109/L, hae-
moglobin >12g/dL (male) or >11g/dL (female), creatinine 
clearance (estimated using Cockcroft-Gault) ≥60ml/min, inter-
national normalised ratio (INR) <1.5). Individuals co-infected 
with HIV were eligible if HIV VL had been <50 copies/ml for 
>24 weeks on anti-HIV drugs. Participants were excluded if 
they had a history of malignancy within 5 years, any history of 
pre-existing cardiac disease or haemoglobinopathies, or a cur-
rent disorder which may cause ongoing liver disease, may 
negatively impact the participant’s ability to adhere to the study 
or might limit the participant’s life expectancy. Participants 
were also excluded if they were hypersensitive to any of the 
study drugs, currently taking any medication known to interact 
with study medication or had used other investigational prod-
ucts within 60 days of screening. Female participants were 
excluded if lactating, pregnant, planning to become pregnant 
or not willing to use effective contraception (excluding prod-
ucts containing ethinyl-oestradiol) including up to four months 
after the study. Male participants were excluded if they were 
planning pregnancy with a partner or not willing to use 
effective contraception for up to seven months after the study. 
Participants gave written informed consent after explana-
tion of the aims, methods, benefits and potential hazards of the 
trial and before any trial-specific procedures were performed/ 
any blood taken for the trial.
Trial setting
Participants were recruited from 14 UK NHS Hospital 
Trusts: Singleton Hospital, Swansea Bay University Health 
Board; University Hospitals of Leicester NHS Trust; Imperial 
College NHS Trust; St George’s Healthcare NHS Foundation 
Trust; Royal Free Hospital NHS Foundation Trust; Nottingham 
University Hospitals NHS Trust; Royal Surrey County 
Hospital NHS Foundation Trust; Brighton and Sussex University 
Hospitals NHS Trust; John Radcliffe Hospital Oxford Univer-
sity Hospitals NHS Foundation Trust; Glasgow Royal Infirmary 
NHS Greater Glasgow and Clyde; Newcastle Freeman Hospital 
Newcastle Upon Tyne Hospitals NHS Foundation Trust; 
Chelsea and Westminster Hospital NHS Foundation Trust; 
Central and North West London NHS Foundation Trust; and 
Sheffield Teaching Hospitals NHS Foundation Trust.
The main criteria for selecting participating hospitals was 
that they had the potential for recruiting the required number 
of chronic (>6 months) HCV genotype 1a/1b/4 infected 
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Figure 1. Trial schematic. Note: DAA: direct-acting antivirals. The ribavirin randomisation was a partial factorial in those randomised to a 
shorter course than the full licensed duration of therapy (the vast majority of participants recruited to the trial).
participants within the agreed recruitment period. This was 
established by the use of a trial specific site survey. Site also 
needed to meet the following criteria: no competing stud-
ies that would impact on the ability to enrol quickly to the trial; 
turnaround of no more than 7 days for HCV viral load test 
results; ability to provide 24 hour cover for trial patients; local 
governance approval likely to take <3 months.
Randomisation
Participants were randomised 1:1 to variable ultrashort- 
course treatment strategy (VUS) or fixed 56 days of first-
line treatment. Individuals were also randomised 1:1 using a 
factorial design to adjunctive ribavirin or no ribavirin with 
first-line therapy. Randomisation determined duration of 
first-line therapy rather than choice of DAAs which was pre-
specified by the investigator before randomisation based on 
local availability from (i) [genotype 1a/1b] co-formulated 
ombitasvir/paritaprevir/ritonavir once daily plus separate 
dasabuvir once-daily (total 25mg/150mg/100 mg plus 500mg, 
respectively) (ii) [genotype 4] ombitasvir/paritaprevir/ritonavir 
25/150/100mg once-daily (iii) [genotype 1a/1b/4] glecaprevir/
pibrentasvir 300/120mg once-daily (only available after 1 Novem-
ber 2017). Ribavirin dosing was weight-based twice-daily (<75kg 
1000mg/day, ≥75kg 1200mg/day). All drugs were taken orally.
Intervention and procedures
For participants allocated to VUS, the duration of first-line 
therapy varied between 28 and 42 (mean 32; before 1 April 
2017) or 49 (mean 39; after 1 April 2017) days determined by 
the baseline screening VL using a continuous scale (Table 1, 
Table 2, Figure 2). Blinding was not used because the primary 
end-point was an objective measure of viraemia blinded to clini-
cal data measured in routine laboratories without knowledge 
of randomisation.
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Table 1. Duration of first-line treatment in the variable-duration group by protocol 
version.
From HCV VL 
(IU/ml)
To HCV VL (IU/ml) Days if randomised 
before 01/04/2017 (VUS1)
Days if randomised 
after 01/04/2017 (VUS2)
LLOQ 50,000 28 28
50,001 65,000 28 29
65,001 82,500 28 30
82,501 110,000 28 31
100,001 140,000 28 32
150,001 180,000 28 33
175,001 235,000 28 34
225,001 300,000 28 35
300,001 400,000 29 36
400,001 500,000 30 37
500,001 550,000 30 38
550,001 650,000 31 38
650,001 750,000 31 39
750,001 850,000 32 39
850,001 1,100,000 32 40
1,100,001 1,300,000 33 41
1,300,001 1,450,000 34 41
1,450,001 1,700,000 34 42
1,700,001 1,850,000 35 42
1,850,001 2,200,000 35 43
2,200,001 2,400,000 36 43
2,400,001 2,850,000 36 44
2,850,001 3,150,000 37 44
3,150,001 3,600,000 37 45
3,600,001 4,100,000 38 45
4,050,001 4,550,000 38 46
4,550,001 5,250,000 39 46
5,250,001 5,700,000 39 47
5,700,001 6,800,000 40 47
6,800,001 7,100,000 40 48
7,100,001 8,800,000 41 48
8,800,001 upwards 42 49
Note: VUS: variable ultra-short
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All patients failing treatment were retreated as soon as prac-
ticable with 12 weeks of oral sofosbuvir 400mg/ledipasvir 
90mg once-daily and weight-based oral ribavirin twice-daily 
(dosing as above). Treatment failure was defined as (i) two con-
secutive measurements of HCV VL above the lower limit of 
quantification (LLOQ) (taken at least one week apart) after 
two consecutive visits with HCV VL <LLOQ at any time, with 
the latter confirmatory measurement also being >2000 IU/mL, 
or (ii) two consecutive measurements of HCV VL (taken at least 
one week apart) that were >1log
10
 increase above the nadir on 
treatment and >2000 IU/mL at any time.
All participants were followed by the site teams for 24 weeks 
after the end of first-line treatment or re-treatment (where 
applicable) for evaluation of virological response and toxic-
ity. Participants on first-line therapy had clinical assessments 
on days 3, 7, 10, 14, 28 and end of treatment (EOT, where EOT 
was not day-28) followed by weeks 2, 4, 8, 12 and 24 after 
EOT. All outcome measures were assessed at these clinic visits.
Randomisation
Randomisation was performed via a computer-generated 
programme at the STOP-HCV-1 Co-ordinating Centre (MRC 
CTU at UCL). Patients were allocated 1:1 using a factorial 
design to each of: biomarker-stratified variable ultrashort vs 
fixed duration; adjunctive ribavirin or not (a partial factorial 
in those randomised to a shorter course than the full licensed 
duration of therapy). Randomisation was stratified by study 
centre, HCV genotype and study drug regimen using a mini-
misation algorithm incorporating a probabilistic element incor-
porated securely into the online trial database. Randomisation 
determined the duration of first-line therapy rather than the 
choice of DAAs which was pre-specified by the investigator 
before randomisation based on local availability.
Each allocation was generated within the trial database only 
at the point of randomisation after it was confirmed the 
participant was eligible and was to be randomised. Allocations 
were generated using minimisation with a probabilistic element, 
so there was no pre-determined allocation sequence to con-
ceal. To further conceal the potential allocation, study centres 
were not informed of the randomisation strata.








4–5 weeks (28–34 days) 48 (71%) 11 (32%) 59 (58%)
5–6 weeks (35–42 days) 18 (26%) 13 (38%) 31 (30%)
6–7 weeks (42–49 days) 2 (3%) 10 (29%) 12 (12%)
Mean (SD) 32 (4.2) 39 (5.6) 35 (5.7)
Figure 2. Duration of first-line treatment in the variable-duration group. DAA: direct acting antivirals; VUS1: variable ultra-short 1 
(4–6 weeks); VUS2: variable ultra-short (4–7 weeks). Note: Lines represent protocol determined treatment duration according to screening 
viral load (x axis).
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On the day of randomisation, participant eligibility was 
checked at sites and the data confirming eligibility was entered 
onto a case record form and sent to MRC CTU. The data 
was entered onto the database at MRC CTU and checked for 
eligibility again. Once confirmed that the participant was eli-
gible, the database would perform randomisation using the 
computer-generated programme. Sites were then informed 
of the allocation and length of DAA treatment required for 
the participant.
Sample size
A priori power calculation assumed 88% of participants 
would achieve SVR12 on first-line fixed-duration, and that 
SVR12 would be 85% on retreatment (significantly lower 
than the actual retreatment success rate, below), leading to 
an overall cure rate of 98% (first-line plus retreatment) in the 
control group. Assuming 98% cure rate in the fixed-duration 
group, 80% power, one-sided alpha 0.025, and a 5% loss to 
follow-up, 408 participants were needed to demonstrate non- 
inferiority with a 4% margin. The choice of the 4% margin 
was based on clinical judgement and to ensure that overall 
cure rates in the variable-duration group would be well over 
90% if non-inferiority was demonstrated. Interim data were 
reviewed by an independent Data Monitoring Committee 
(DMC) (4 biannual meetings). The protocol stipulated that the 
DMC could alter the first-line treatment strategy if there was 
strong evidence the SVR12 rate for VUS1 was less than 65%. 
After the DMC meeting in April 2017, the DAA duration 
strategy was changed from 4–6 weeks (VUS1) to 4–7 weeks 
(VUS2) (Table 1). All participants randomised from the 1st 
April 2017 were treated under VUS2. The trial closed in 
August 2018 when no further recruitment was possible. By 
this time, the great majority of patients with viraemia were 
unable to engage with treatment per se, and not suitable for 
inclusion in this study.
Outcomes
The primary outcome was sustained virological response 
12 (SVR12, plasma HCV VL <LLOQ without prior failure 12 
weeks after the end of the combined first and any re-treatment 
phases). For ribavirin comparison the primary outcome was 
SVR12 after first-line treatment only. Secondary outcomes 
were SVR12 after first-line treatment (where not the primary 
outcome), SVR12 after the end of the combined first and any 
re-treatment phases (where not the primary outcome), SVR24 
(24 weeks) after the end of the combined first and any 
re-treatment phases, SVR24 after first-line treatment only, 
lack of initial virological response, viral load rebound after 
becoming undetectable, serious adverse events, grade 3/4 
adverse events, grade 3/4 adverse events judged definitely/prob-
ably related to interventions, treatment-modifying adverse events 
(any grade), grade 3/4 anaemia and emergence of resistance- 
associated HCV variants. Adverse events were graded fol-
lowing the Division of AIDS grading tables. Full genome 
sequence was obtained by RNA Sequencing on Illumina Miseq 
platform following target enrichment with a library of genotype 
specific HCV capture probes as described previously16.
Statistical analysis
Randomised groups were compared following the princi-
ple of intention-to-treat (including all follow-up regardless of 
changes to treatment) using binomial regression (risk differ-
ence scale) to estimate risk differences for binary outcomes, 
Kaplan-Meier and Cox regression for time to first-line failure 
(with competing risks methods for its components, primary fail-
ure and VL rebound), and generalised estimating equations with 
independent working correlation for global tests of repeated 
measures (adjusted for baseline for continuous measures). A 
per-protocol analysis included patients receiving >90% and 
<100% of the prescribed duration of first-line treatment and 
where the difference between screening and enrolment HCV 
RNA values would have led to a difference of ≤2 days in 
allocated duration of DAAs had they been allocated to the 
variable-duration group. Primary analyses of outcomes 
restricted to first-line therapy were stratified by first-line DAA 
strategy in place (VUS1 (before 1 April 2017) or VUS2 (after 
1 April 2017)) as a main effect, and as an interaction with 
randomised group (fixed-duration vs variable-duration), where 
the p-value for the interaction term was <0.05. Primary analyses 
of outcomes including retreatment were unstratified, reflect-
ing the overall strategy comparison and because no patients 
failed after receiving retreatment. Analyses used Stata v15.1. No 
adjustment was made for multiple testing. All subgroups within 
the subgroup analyses were pre-specified in the protocol. 
Further information on statistical methods and results can 
be found as extended data17.
Results
Between 18 March 2016 and 28 August 2018, 204 participants 
from 14 UK centres were randomised (Figure 3). Two par-
ticipants were randomised in error and excluded, leaving 202 
(102 fixed-duration, 100 variable-duration; 100 ribavirin, 
102 no-ribavirin) participants in the analyses18.
Baseline characteristics were broadly balanced between ran-
domised groups (Table 3) and across strategies (before vs after 
1 April 2017). Median screening and enrolment HCV VL 
were 711423 and 741946 IU/mL in samples taken a median 
(IQR) 19 (13,33) days apart. Whilst the median (IQR) differ-
ence was 0.01 (-0.19,+0.21) log
10
 IU/mL, absolute differences 
were greater (Figure 4), leading to 57 (28%) participants being 
excluded from the per-protocol analysis because they would 
have received a difference of ≥3 days of DAAs had this been 
determined by the enrolment rather than the screening VL (31 
(23%) VUS1 vs 26 (39%) VUS2, because the second strategy 
received more drug overall).
Follow-up and treatment received
Each pre- or post- first-line EOT visit was missed by no 
more than eight (4%) participants. One participant was lost-
to-follow-up at day-28 on first-line and three (all randomised 
to fixed-duration, two with ribavirin) stopped first-line treat-
ment >1 week early. All other participants completed first-line 
treatment (Figure 5). Adverse events caused one participant 
to stop both first-line DAAs and ribavirin three days early 
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Figure 3. Trial profile. Note: EOT+12: 12 weeks after the end of treatment; EOT+24 24 weeks after the end of treatment. Some patients lost 
to follow up are included in the analysis based on local VLs from clinics.
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Table 3. Characteristics at randomisation.








Randomised under first protocol (VUS1) 136 (67%) 68 (68%) 68 (67%) 68 (68%) 68 (67%)
Age (years) 45.5 (37.5, 53.0) 45.2 (38.8, 
51.6)




Female at birth 62 (31%) 28 (28%) 34 (33%) 34 (34%) 28 (27%)
BMI (kg/m2) 24.9 (22.2, 27.2) 24.9 (22.6, 
26.7)




White ethnicity 176 (87%) 89 (89%) 87 (85%) 89 (89%) 87 (85%)
Weight (kg) 74.0 (66.0, 84.6) 73.0 (65.9, 
84.1)


























HCV genotype/subgenotype: 1a 166 (82%) 82 (82%) 84 (82%) 84 (84%) 82 (80%)
              1b 34 (17%) 17 (17%) 17 (17%) 16 (16%) 18 (18%)
              4 2 (1%) 1 (1%) 1 (1%) 0 2 (2%)
HIV coinfected 68 (34%) 32 (32%) 36 (35%) 35 (35%) 33 (32%)
Fibroscan result (kPa) 4.9 (4.2, 5.8) 5.0 (4.3, 5.9) 4.8 (4.1, 5.5) 4.8 (4.4, 
5.8)
4.9 (4.1, 5.9)
Haemoglobin (g/dl) 14.7 (14.0, 15.6) 14.8 (14.1, 
15.6)




ALT (IU/ml) 52 (34, 87) 50 (34, 90) 54 (34, 87) 51 (35, 89) 54 (31, 87)
AST (IU/l) n=189 38 (30, 57) 38 (29, 57) 38 (31, 58) 39 (31, 55) 38 (29, 58)
ALP (IU/l) 72 (59, 91) 71 (59, 87) 75 (59, 94) 76 (61, 95) 69 (58, 85)
eGFR (ml/min) 109 (93, 131) 109 (94, 126) 109 (92, 138) 107 (92, 
126)
110 (93, 133)
Total bilirubin (umol/l) 9 ( 6, 12) 8 (6, 11) 9 (6, 12) 9 (6, 12) 9 (6, 12)
IL28b genotype*: CC 60 (30%) 32 (32%) 28 (27%) 29 (29%) 31 (30%)
              CT 106 (52%) 51 (51%) 55 (54%) 56 (56%) 50 (49%)
              TT 27 (13%) 14 (14%) 13 (13%) 11 (11%) 16 (16%)
              No result 9 (4%) 3 (3%) 6 (6%) 4 (4%) 5 (5%)
Previously unsuccessfully treated with 
interferon and/or ribavirin
24 (12%) 12 (12%) 12 (12%) 11 (11%) 13 (13%)
Ever spontaneously cleared and re-
infected
6 (3%) 4 (4%) 2 (2%) 2 (2%) 4 (4%)
Ever successfully treated with interferon 
and/or ribavirin and re-infected
10 (5%) 5 (5%) 5 (5%) 5 (5%) 5 (5%)
Current/recent alcoholism/alcohol abuse 13 (6%) 5 (5%) 8 (8%) 7 (7%) 6 (6%)
Current/recent illicit substance abuse 64 (32%) 31 (31%) 33 (32%) 28 (28%) 26 (25%)
Treated with paritaprevir\ombitasvir\
dasabuvir
198 (98%) 98 (98%) 100 (98%) 100 (100%) 98 (96%)
Treated with paritaprevir\ombitasvir 2 (1%) 1 (1%) 1 (1%) 0 2 (2%)
Treated with glecaprevir\pibrentasvir 2 (1%) 1 (1%) 1 (1%) 0 2 (2%)
* Result from whole genome sequencing or from Epistem point of care test if genotyping result not available.
Note: showing n (%) for categorical factors, or median (IQR) for continuous factors. Missing data indicated by denominators in the row label. As an indicator 
of imbalance, P>0.05 for all comparisons of baseline characteristics between groups other than BMI (p<0.001), weight (p=0.003) and ALP (p=0.04) between 
ribavirin and no ribavirin groups.
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Figure 4. HCV VL at screening and enrolment by assay.
Figure 5. Self-reported treatment duration and first-line SVR24. Note: Lines represent protocol determined treatment duration 
according to screening viral load (x axis). Symbols represent self-reported individual duration of therapy. Patients could stop DAAs early 
for adverse events or personal reasons, and take DAAs for longer than prescribed if any missed doses were taken at the end of treatment. 
Excludes one patient lost-to-follow-up during first-line whose outcome on first-line is unknown.
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(grade 3 mouth sores), and one ribavirin only two days early 
(grade 3 anaemia). Self-reported non-adherence to DAAs 
and/or ribavirin varied from 2–14% across first-line visits 
(Figure 6(a)), with 55 (28%) reported missing doses at any 
first-line visit (40 (20%) at one visit only). Each retreatment 
visit was missed by at most four (6%) participants, with the 
exception of week-8 post-retreatment (missed by 10 (16%) 
participants). Self-reported non-adherence was substantially 
higher on retreatment (Figure 6(b)), 12–19% across visits, 24 
(39%) at any retreatment visit, 17 (27%) at one retreatment 
visit only).
Sustained virological response (SVR)
One participant withdrew consent (retreatment week-4) and 
a further 13 (6%) participants were lost-to-follow-up (1 on 
first-line, 9 post first-line EOT, 2 on retreatment, 1 post retreat-
ment EOT; total withdrawn/lost 9 (9%) fixed-duration, 4 (4%) 
variable duration). However, HCV VL results were available 
from medical notes for most of those not withdrawing consent, 
meaning first-line SVR12 and SVR24 could not be ascer-
tained for only 3 (1%) and 6 (3%) participants, respectively 
(1/2 and 3/3 fixed/variable-duration, respectively), and overall 
(first-line plus retreatment) SVR12 and SVR24 for only 5 (2%) 
and 8 (4%) participants (2/3 and 4/4 fixed/variable-duration) 
respectively.
Overall, all evaluable participants achieved SVR12 (and 
SVR24) on first-line plus retreatment (primary outcome for 
fixed vs variable-duration randomisation) (100% (95%CI 
96%,100%) in both groups, difference 0% (95%CI (Newcombe) 
-3.8%,+3.7%), within the pre-specified 4% non-inferiority 
margin).
First-line SVR12 (secondary outcome) was 91% (95% CI 
86%,97%; 92/101) in the fixed-duration group vs 48% (39,57%; 
47/98) in the variable-duration group (Figure 7(a); difference 
-43% (95% CI -54%,-32%), p<0.0001). However, SVR12 was 
significantly higher for VUS2 (72% (56%,87%); 23/32) than 
VUS1 (36% (25%,48%); 24/66) (interaction between duration 
randomisation and strategy p=0.001). First-line SVR12 was 
72% (65%,78%); 70/101) with ribavirin and 68% (61%,76%; 
69/98) without (difference -3% (-13%, +6%) p=0.48 adjusting 
for interaction between duration randomisation and strategy). 
There was no evidence of interaction between ribavirin and 
duration randomisations overall (heterogeneity p=0.16 adjusted 
for the interaction between duration randomisation and strat-
egy) or in the variable-duration group, where SVR12 was 52% 
(37%,67%; 25/48) with ribavirin vs 44% (30%,59%; 22/50) 
without ribavirin (difference 8% (95% CI -10%,+27%), p=0.38).
The difference in first-line SVR12 between fixed-duration vs 
variable-duration was significantly smaller in 2 of 16 subgroups 
pre-specified in the protocol, suppression at day-7 or day-14 
(heterogeneity p=0.02, 0.03 respectively) (Figure 7(b) and 
Figure 8). Considering the time when individuals first became 
undetectable , all 10 individuals who became undetectable 
at day-3 of treatment achieved first-line SVR12 regard-
less of treatment duration (as did 31/38 (82%) of those first 
undetectable at day-7) (Figure 7(c)). In the ribavirin randomi-
sation, no subgroup had a difference that was significantly 
larger or smaller (Figure 9).
In total, 70 (70%) receiving VUS1/VUS2 vs 72 (71%) receiving 
fixed-duration were included in the per-protocol population 
and 68 (68%) receiving ribavirin vs 74 (73%) not receiving 
ribavirin (received >90% and <100% of the prescribed duration 
of first-line treatment and had a difference between screening 
and enrolment HCV RNA values leading to a difference 
of ≤2 days in allocated duration of DAAs had they been 
allocated to the variable-duration group). For the duration ran-
domisation SVR12, after first-line and any retreatment was 100% 
overall (95% CI 97%, 100%) with a difference of 0% (95% CI 
(Newcombe) -5%, +5%). SVR12 after first-line only was 47% 
(95% CI 36%, 59%; 32/69) in the variable-duration group vs 
93% (95% CI 87%, 99%; 66/71) in the fixed-duration group. 
The difference was -46% (95% CI -59%, -33%; p<0.0001). 
For the ribavirin randomisation, SVR12 after first-line and any 
retreatment was 100% overall (95% CI 97%, 100%) with a 
difference of 0% (95% CI (Newcombe) -0.06%, +0.05%). 
SVR12 after first-line only was 70% (95% CI 61%, 78%; 48/66) 
in the ribavirin group vs 70% (95% CI 62%, 78%; 50/74) in the 
no ribavirin group. The difference was -0% (95% CI -11%, 
+10%; p=0.93).
Results were similar for SVR24. For the duration randomisa-
tion, SVR24 after first-line and any retreatment was 100% 
overall (95% CI 98%, 100%; 194/194) with a difference of 0% 
(95% CI (Newcombe) -3.8%, +3.8%). SVR24 after first-line 
only was 47% (95% CI 38%, 56%; 46/97) in the variable- 
duration group vs 89% (95% CI 83%, 95%; 88/99) in the 
fixed-duration group. The difference was -42% (95% CI -53%, 
-31%; p<0.0001). For the ribavirin randomisation, SVR24 after 
first-line and any retreatment was 100% overall (95% CI 95%, 
100%); 194/194) with a difference of 0% (95% CI (Newcombe) 
-3.8%, 3.8%). SVR24 after first-line only was 69% (95% CI 
61%, 76%; 68/97) in the ribavirin group vs 68% (95% CI 
60%, 76%; 66/99) in the no ribavirin group. The difference 
was 1% (95% CI -9%, +11%; p=0.87).
Timing of failure
Only 1 (0.5%) (VUS1) participant failed on treatment (at 
EOT, 28 days DAAs). 21 (10%) participants had primary 
first-line failure (VL never confirmed undetectable) (5 (5%) 
fixed-duration vs 16 (16%) variable-duration, p=0.008, 
Figure 10(a)); in the variable-duration group, primary fail-
ure occurred in 16 (24%) VUS1 vs 0 (0%) VUS2 (p=0.002; 
interaction not estimable across strategies). 41 (20%) partici-
pants had VL rebound after confirmed undetectable HCV VL 
(6 (6%) fixed-duration vs 35 (35%) variable-duration, p<0.0001, 
Figure 10(b); 26 (38%) VUS1, 9 (28%) VUS2, heterogeneity 
p=0.60). There was no evidence that ribavirin was associ-
ated with primary failure (p=0.83) or rebound (p=0.59) 
(Figure 11). Failure tended to occur earlier with VUS1 vs VUS2 
(p=0.08), and with variable-duration vs fixed-duration (p=0.07; 
VUS1 vs fixed-duration p=0.03). However, there was no 
evidence of differences in failure VLs (median 158073 
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Figure 6. Reported missing doses by ribavirin randomisation. (a) First-line treatment. (b) Retreatment.
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Figure 7. SVR12. (a) overall SVR12, and first-line SVR12 by randomised groups and strategies (VUS1/VUS2). (b) variation in the difference 
between fixed-duration vs variable-duration in first-line SVR12 by key subgroups. (c) first-line SVR12 by time first suppressed. Note: FL=first-
line, RT=retreatment. Fixed = overall SVR12 for 8 week therapy. Fixed1=fixed duration when VUS duration received VUS1, Fixed2=fixed 
duration when VUS duration received VUS2. In panel (b), solid bars represent the first subgroup (detectable VL at the various days shown, no 
previous unsuccessful treatment, no baseline resistance to drugs taken first-line) and empty bars the second subgroup (undetectable VL at 
the various days shown, previous unsuccessful treatment, baseline resistance to drugs taken first-line). p-values are heterogeneity p-values 
comparing the difference between fixed vs VUS1/VUS2 strategies across the two subgroups. Heterogeneity p-value for D3 VL cannot be 
estimated due to perfect prediction. Panel (c) does not include 8 patients who never had VL suppression; for patients allocated 28–31 days, 
their EOT visit is also their 28 day visit and they are included in each group.
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Figure 8. Subgroup analyses for first-line SVR12 by fixed-duration vs variable-duration randomisation. Note: RAS=resistance 
associated substitution. All heterogeneity tests also adjusted for the interaction between strategy and fixed-duration vs variable-duration 
randomisation. Some confidence intervals and heterogeneity p-values could not be estimated due to perfect prediction.
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Figure 9. Subgroup analyses for first-line SVR12 by ribavirin randomisation. Note: RAS=resistance associated substitution. All 
heterogeneity tests also adjusted for the interaction between strategy and fixed-duration vs variable-duration randomisation. Some 
confidence intervals and heterogeneity p-values could not be estimated due to perfect prediction. All participants with genotype 4 did not 
receive ribavirin so not included.
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Figure 10. Time to failure on first-line by fixed duration vs variable duration randomisation. (a) Primary first-line failure (never 
confirmed detectable). (b) HCV VL rebound (after confirmed detectable).
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Figure 11. Time to failure on first-line by ribavirin randomisation. (a) Primary first-line failure (never confirmed detectable). (b) HCV 
VL rebound (after confirmed detectable).
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(VUS1), 89125 (VUS2), 346737 (fixed-duration), p(VUS2 vs 
VUS1)=0.41, p(VUS2 vs fixed-duration)=0.21). All participants 
who met failure criteria on first-line started retreatment, a 
median (IQR) 2.9 (2.0,4.4) weeks after failure was confirmed.
Corresponding to the timing of failures, the percentages with 
undetectable VL decreased more rapidly post-EOT in VUS1 
vs VUS2 (p<0.0001) or VUS1 vs fixed-duration (p<0.0001) 
(Figure 12(a)). There was no evidence of differences in the 
proportions with detectable VL at EOT in VUS1 compared 
to VUS2 (p=0.33) or fixed-duration (p=1.00). There was no 
evidence that ribavirin was associated with higher percentages 
detectable post-EOT overall (p=0.48) or, within the variable-group, 
between VUS1 vs VUS2 (interaction p=0.17, Figure 12(b)).
Emergence of resistance
In total, 14 participants who failed on first-line treatment 
developed a new resistance mutation (not present at baseline) to 
at least one of their prescribed drugs (Table 4, Table 5). Within 
paired samples available at baseline and failure, there was no 
evidence of a difference in emergent resistance between 
fixed-duration and variable-duration (3/10 (30%) vs 11/46 (24%, 
respectively, p=0.77). However, ribavirin was associated with 
lower emergence of resistance to first-line drugs (3/27 (11%) 
with vs 11/29 (38%) without ribavirin, p=0.01; Figure 13) 
with significantly lower rates of resistance to any DAA and to 
NS5a inhibitors (both p=0.01).
Adverse events
Overall, five (5%) variable-duration vs five (5%) fixed- 
duration participants experienced serious adverse events (SAEs) 
(hazard ratio (HR)=0.77 (95% CI 0.21,2.80) p=0.69) and nine 
(9%) vs five (5%) respectively experienced Grade 3/4 adverse 
events (AEs) (HR=1.74 (0.58,5.24) p=0.33) (Table 6, Table 7). 
Similarly, five (5%) ribavirin vs five (5%) no ribavirin partici-
pants experienced SAEs (HR=1.05 (95% CI 0.30,3.63) p=0.59) 
and nine (9%) vs five (5%) respectively experienced Grade 
3/4 AEs (HR=1.92 (0.64,5.72) p=0.59) (Table 7, Table 8). 
Treatment-related AEs, AEs causing changes to treatment and 
Grade 3/4 anaemia were all uncommon (Table 6); all Grade 
3/4 anaemias occurred in participants randomised to adjunc-
tive ribavirin (p=0.12) as did all first-line drug changes 
for AEs (p=0.06) (Table 8). 
Discussion
This large strategic post licensing trial demonstrated overall 
non-inferiority of strategies using first-line ultrashort treatment 
durations, with both variable duration and fixed duration 
groups achieving 100% SVR12 rate after retreatment. The 
initial shortening strategy (VUS1) was able to cure only 
36% of participants first-line but, strikingly, a relatively small 
increase in ultrashort treatment duration (from a mean of 32 days 
to 39 days) resulted in a doubling of SVR12 rates (from 36% 
to 72%). The 8-week fixed-duration strategy, with an SVR12 
of 91%, did not have higher efficacy than previous phase II 
trials of shorter treatment courses19, despite limiting the maxi-
mal baseline viral load in those enrolled, which might have 
been expected to reduce the risk of failure. The trial’s findings 
suggest a high proportion of patients can be cured with, on 
average, approximately 60% of the licensed duration of 
first-line therapy with the agents used in the trial (VUS2 
strategy). However, first-line cure rates were not sufficient to 
be routinely recommended for stable patients able to adhere to 
8–12 weeks’ therapy.
Previous work has found adherence to DAA therapy declines 
as treatment progresses, with patients citing “feeling as if the 
treatment is working” as a reason for decreasing adherence5. 
Despite trial participants generally being considered to have 
better adherence, we found similarly decreasing adherence with 
time on first-line, with 28% reporting missed first-line doses, 
and poorer adherence to retreatment (despite its 100% SVR12) 
(Figure 5). That we observed 72% SVR12 with VUS2 (mean 
duration 39 days) despite 28% reporting missing doses, 
suggests that intermittent non-adherence may be less important 
than overall adherence during weeks 4 to 8 of first-line treat-
ment, and emphasise the importance of supporting adherence 
after week 4 of therapy to ensure good cure rates in hard-to- 
reach populations10,20.
The risk of virological failure, in a patient unlikely to 
complete the recommended treatment course, is a clinical concern. 
Emergent resistance could compromise retreatment, particu-
larly where retreatment does not include a protease inhibitor (as 
in this trial, in contrast to licensed retreatment options). This is 
also an ethical consideration in short-course therapy trials. 
We found the first-line treatment strategy did not compromise 
participants’ ability to ultimately achieve SVR12. Whether this 
would be the case with pan-genotypic first-line treatment 
regimens remains to be tested, although it seems plausible. The 
100% SV12 rates for retreatment is reassuring from an ethical 
perspective and suggests that, in certain circumstances, the com-
bination may represent a viable retreatment option for patients 
failing therapy where access to licensed retreatment options 
(such as sofosbuvir/velpatasvir/voxilaprevir) remains limited. 
Although ribavirin side-effects, particularly anaemia and 
fatigue, increasingly limit its use2,12 it still has a role for some 
patients13 with limited evidence that it can increase efficacy21 
and in vitro evidence that it may reduce the emergence of 
resistance with short course therapy22. Here, additional riba-
virin was well tolerated, with only 2–4% participants experi-
encing adverse events. Across randomised groups, there was 
no evidence of improvement in SVR12. However, the emer-
gence of resistance was significantly lower in those failing 
therapy (12% with ribavirin v 38% without), the first time this 
has been demonstrated in a randomised trial. This suggests 
that adjunctive ribavirin may have a role for some patients 
considered at high risk of not completing therapy in order to 
reduce the risk of compromising retreatment and further work 
is required to understand better the mechanism of action in 
this setting.
Response-guided therapy, shortening treatment based on initial 
virological response, was commonplace for interferon-based 
therapy23 but this approach is not currently recommended 
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Figure 12. HCV VL suppression first-line. (a) By duration randomisation. Note: EOT=end of treatment. Carrying forward last detectable 
value for participants meeting failure criteria. No evidence of difference between groups through day 28 when all participants were 
receiving DAAs (global p=0.13 comparing fixed-duration vs variable-duration combined; p=0.10 and 0.82 comparing VUS1 and VUS2 vs 
fixed, respectively). Post-EOT global p<0.0001 comparing fixed-duration vs variable-duration combined; p<0.0001 and 0.53 comparing 
VUS1 and VUS2 vs fixed, respectively. (b) By ribavirin randomisation. Note: EOT=end of treatment. Carrying forward last detectable value for 
participants meeting failure criteria. No evidence of difference between groups through day 28 when all participants were receiving DAAs 
(global p=0.62 comparing ribavirin vs no ribavirin (combining fixed-duration vs variable-duration combined); interaction p=0.28). Post-EOT 
global p=0.48 comparing ribavirin vs no ribavirin (combining fixed-duration vs variable-duration combined; interaction p=0.22).
Page 20 of 29
Wellcome Open Research 2021, 6:93 Last updated: 14 MAY 2021
Table 4. Summary of RAS to any DAA in genotype 1a by 
time point.
Baseline Post-failure
Resistance to NS5a inhibitors N=13 N=18
24: K24R 1 (8%) 2 (11%)
28: M28T - 5 (28%)
      M28V 6 (46%) 5 (28%)
30: Q30H 1 (8%) -
      Q30L - 1 (6%)
      Q30R - 6 (33%)
31: L31M - 2 (11%)
58: H58D - 2 (11%)
93: Y93F 1 (8%) -
      Y93H - 1 (6%)
      Y93N 1 (8%) 1 (6%)
Resistance to NS5b inhibitors N=7 N=3
448: Y448H 2 (29%) -
556: S556G 5 (71%) 3 (100%)
Resistance to protease inhibitors N=30 N=14
36: V36M 1 (3%) 1 (7%)
55: V55A 3 (10%) 2 (14%)
      V55I 3 (10%) 1 (7%)
80: Q80K 21 (70%) 9 (64%)
      Q80L 1 (3%) -
155: R155K - 1 (7%)
168: D168A - 1 (7%)
Table 5. Summary of RAS to any DAA genotype in 1b by 
time point.
Baseline Post failure
Resistance to NS5a inhibitors N=13 N=2
30: R30Q 1 (8%) -
31: L31I 1 (8%) -
      L31M 1 (8%) -
37: L37I 1 (8%) -
54: Q54H 11 (84%) 2 (100%)
58: P58S 1 (8%) -
Resistance to NS5b inhibitors N=10 N=3
159: L159F 5 (50%) 1 (33%)
316: C316H 2 (20%) 1 (33%)
        C316N 4 (40%) 1 (33%)
556: S556G 6 (60%) 3 (100%)
Resistance to protease inhibitors N=2 N=1
122: S122N 1 (50%) 1 (100%)
168: D168E 1 (50%) -
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Figure 13. Resistance at baseline (all tested participants) and at first-line failure (failures only). Note: DAA: direct acting antivirals. 
p-values are comparing any resistance, to first-line drug or any other DAA, between ribavirin groups. Coloured bars represent resistance to 
drugs received first-line, white bars, all DAAs including those not used in the trial.
Table 6. Summary of adverse events by fixed duration vs variable duration randomisation.
Variable-duration Fixed-duration Total p-value*
Number randomised N=100 N=102 N=202






SAEs 5 (5%) [5] 5 (5%) [5] 10 (5%) [10] p=1.00
Life-threatening 1 (1%) [1] 1 (1%) [1] 2 (1%) [2]
Required or prolonged hospitalisation 5 (5%) [5] 4 (4%) [4] 9 (4%) [9]
Other important medical condition 0 1 (1%) [1] 1 (<1%) [1] 
Relationship to trial drug (% of SAEs)
Unlikely 2 (40%) 2 (40%) 4 (40%)
Not related 3 (60%) 3 (60%) 6 (60%) 
Severe AEs 9 (9%) [16] 5 (5%) [5] 14 (7%) [21] p=0.28
Relationship to trial drug (% of severe AEs)
Definitely 8 (50%) 0 8 (38%) 
Probably 2 (13%) 2 (40%) 4 (19%) 
Possibly 3 (19%) 0 3 (14%) 
Unlikely 0 1 (20%) 1 (5%) 
Not related 3 (19%) 2 (40%) 5 (24%) 
AEs probably/definitely related to first-line drugs 3 (3%) [3] 1 (1%) [1] 4 (2%) [4] p=0.37
AEs probably/definitely related to retreatment drugs 3 (3%) [7] 1 (1%) [1] 4 (2%) [8] p=0.37
First-line drug changes due to AEs 3 (3%) [3] 1 (1%) [1] 4 (2%) [4] p=0.37
Retreatment drug changes due to AEs 6 (6%) [11] 1 (1%) [1] 7 (3%) [12] p=0.06
Grade 3/4 anaemia 3(3%) [3] 0 3 (1%) [3] p=0.12
*p-values calculated using chi-square tests or Fishers exact test when numbers are small.
Note: no. of patients (% of patients) [no. of events]. Tables include data for both first-line and retreatment phases. For SAEs, HR=0.77 (0.21, 2.80) 
p=0.69. For severe (grade 3/4 AEs), HR=1.74 (0.58, 5.24) p=0.33.
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Accidental drug overdose* 1 0 0 0 1
Acute appendicitis 0 0 0 1 1
Adenocarcinoma in lower third of oesophagus* 0 0 0 1 1
Burn to foot - degree unknown 1 0 0 0 1
Liver abscess 1 0 0 0 1
Lower respiratory tract infection - pneumonia 1 0 0 0 1
Musculoskeletal pain in chest radiating to left 
arm 
0 0 0 1 1
Pericarditis 1 0 0 0 1
R epididymo-orchitis 0 0 0 1 1
Urinary sepsis 0 0 0 1 1
Severe AEs
Abscess leg 01 0 0 0 1
Alcohol intoxication acute 0 0 0 1 1
Anaemia 2 0 0 0 2
Cellulitis of leg 0 1 1 0 2
Concentration loss 1 0 0 0 1
Haemoglobin low 1 0 0 0 1
Hyperbilirubinemia 0 1 0 0 1
Inguinal hernia 1 0 0 0 1
Insomnia 3 0 0 0 3
Jaundice 0 0 0 1 1
Lethargic 1 0 0 0 1
Low mood 1 0 0 0 1
Pyelonephritis 0 0 1 0 1
Sores mouth 1 0 0 0 1
Suicidal ideation 1 0 0 0 1
Syncope 0 0 0 1 1
Tinnitus 1 0 0 0 1
AEs probably/definitely related to trial drugs
Anaemia 2 0 0 0 2
Concentration loss 1 0 0 0 1
Haemoglobin low 1 0 0 0 1
Hyperbilirubinemia 0 1 0 0 1
Insomnia 3 0 0 0 3
Jaundice 0 0 0 1 1
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Table 8. Summary of adverse events by ribavirin randomisation.
With ribavirin Without ribavirin Total p-value*
Number randomised N=100 N=102 N=202






SAEs 5 (5%) [5] 5 (5%) [5] 10 (5%) [10] p=1.00
SAE criteria
Life-threatening 1 (1%) [1] 1 (1%) [1] 2 (1%) [2]
Required or prolonged hospitalisation 5 (5%) [5] 4 (4%) [4] 9 (4%) [9]
Other important medical condition 0 1 (1%) [1] 1 (<1%) [1]
Relationship to ribavirin (% of SAEs)
Unlikely 2 (40%) 2 (40%) 4 (40%) 
Not related 3 (60%) 3 (60%) 6 (60%)
Severe AEs 9 (9%) [15] 5 (5%) [6] 14 (7%) [21] p=0.28
Relationship to trial drug (% of severe AEs)
Definitely 8 (53%) 0 8 (38%) 
Probably 1 (7%) 3 (50%) 4 (19%) 
Possibly 3 (20%) 0 3 (14%) 











Lethargic 1 0 0 0 1
Low mood 1 0 0 0 1
Syncope 0 0 0 1 1
Tinnitus 1 0 0 0 1
Drug changes due to AEs
Anaemia 3 3 0 0 6
Concentration loss 1 0 0 0 1
Haemoglobin low 1 0 1 0 2
Hair loss 0 0 1 0 1
Hyperbilirubinemia 0 1 0 0 1
Insomnia 1 0 0 0 1
Lethargic 1 0 0 0 1
Low mood 1 0 0 0 1
Mouth ulcer 1 0 0 0 1
Sores mouth 1 0 0 0 1
*Life-threatening events
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for DAA therapy24,25. Our findings suggest, for the first time, 
that very early responses to treatment (undetectable at day-3, or 
even day-7) may be helpful in predicting success of shortened 
treatment courses. Whilst not widely applicable, in specific 
supervised clinical settings (including in-patients, prisoners 
or directly observed daily therapy in the community) such an 
approach may help guide management and deserves further 
confirmation in prospective studies25–27.
This trial was designed to test treatment strategies, rather than 
specific regimens. Almost all recruitment happened when 
ombitasvir, paritaprevir, dasabuvir and ritonavir (Viekirax, 
Abbvie) was the preferred first-line treatment in the UK National 
Health Service (NHS). This combination remains a recom-
mended NHS option, part of the WHO Essential Medicines 
List and is used in a number of countries. However, its use has 
been superceded by pangenotypic options in many settings and 
the extent to which these findings can be generalised to other 
combinations with broader genotype coverage is unknown. 
Give the similar declines in HCV VL between this and other 
DAA combinations (Figure 12), it seems plausible that the rela-
tionship between treatment duration and SVR12 is similar for 
other DAAs combinations approved for 12 weeks for patients 
with mild disease.
The trial required a population able to adhere to a sched-
ule with significantly more visits than standard of care. Non- 
attendance was low and self-reported adherence reasonably 
high (Figure 5), despite one-third participants actively using 
recreational drugs. Following expanded access to DAA ther-
apy, trial recruitment completed short of its original target when 
there were very few patients in need of treatment able to adhere 
to the follow-up schedule. However, higher than anticipated 
success of retreatment (predicted to be 85%, actually 100%) 
and lower than expected loss to follow-up meant that the 
trial was able to demonstrate non-inferiority according to its 
pre-specified margin, providing confidence that either strategy 
would result in an overall SVR12 rate of at least 96% (higher 
than originally specified).
The treatment of individuals who are unlikely to complete 
recommended treatment courses is crucial for elimination 
strategies. Our findings suggest that ultrashort-courses of 
treatment can cure a significant proportion of patients with 
mild liver disease, without compromising retreatment in those 
not cured. Additional ribavirin in those unlikely to complete a 




Figshare: STOP-HCV-1 trial data. https://doi.org/10.6084/
m9.figshare.14141411.v118
This project contains the following underlying data:
-  figsharedata.csv (Raw dataset containing baseline 
demographics, outcomes and VL results)
Extended data
Figshare: STOP-HCV-1 supplementary material. https://doi.
org/10.6084/m9.figshare.14229212.v117
This project contains the following extended data:
-  STOP-HCV-1 supplementary material.docx 
(Supplementary methods and results)
Reporting guidelines
Figshare: CONSORT checklist for ‘Strategic treatment 
optimization for HCV (STOPHCV1): a randomised control-
led trial of ultrashort duration therapy for chronic hepatitis C’. 
https://doi.org/10.6084/m9.figshare.14216063.v114
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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With ribavirin Without ribavirin Total p-value*
Not related 2 (13%) 3 (50%) 5 (24%) 
AEs probably/definitely related to first line drugs 3 (3%) [3] 1 (1%) [1] 4 (2%) [4] p=0.37
AEs probably/definitely related to retreatment drugs 2 (2%) [6] 2 (2%) [2] 4 (2%) [8] p=1.00
First line drug changes due to AEs 4 (4%) [4] 0 4 (2%) [4] p=0.06
Retreatment drug changes due to AEs 4 (4%) [8] 3 (3%) [4] 7 (3%) [12] p=0.72
Grade 3/4 anaemia 3(3%) [3] 0 3 (1%) [3] p=0.12
*p-values calculated using chi-square tests or Fishers exact test when numbers are small.
Note: no. of patients (% of patients) [no. of events]. Tables include data for both first-line and retreatment phases. For SAEs, HR=1.05 (95% CI 0.30, 
3.63) p=0.94. For severe (grade 3/4 AEs), HR=1.92 (0.64, 5.72) p=0.59.
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